ATE418969T1 - Carvedilol enthaltende pharmazeutische zusammensetzung mit kontrollierter freisetzung - Google Patents

Carvedilol enthaltende pharmazeutische zusammensetzung mit kontrollierter freisetzung

Info

Publication number
ATE418969T1
ATE418969T1 AT06779688T AT06779688T ATE418969T1 AT E418969 T1 ATE418969 T1 AT E418969T1 AT 06779688 T AT06779688 T AT 06779688T AT 06779688 T AT06779688 T AT 06779688T AT E418969 T1 ATE418969 T1 AT E418969T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
controlled release
release pharmaceutical
composition containing
containing carvedilol
Prior art date
Application number
AT06779688T
Other languages
English (en)
Inventor
Pal Fekete
Zoltan Budavari
Zsolt Zsigmond
Agnes Bozso
Huszar Magdolna Leventiszne
Zoltanne Palfi
Palne Szentgroti
Karacs Erika Davidne
Kuncze Aniko Turoczine
Krisztina Abraham
Original Assignee
Egis Gyogyszergyar Nyilvanosan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Gyogyszergyar Nyilvanosan filed Critical Egis Gyogyszergyar Nyilvanosan
Application granted granted Critical
Publication of ATE418969T1 publication Critical patent/ATE418969T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06779688T 2005-08-26 2006-08-23 Carvedilol enthaltende pharmazeutische zusammensetzung mit kontrollierter freisetzung ATE418969T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0500803A HU227490B1 (en) 2005-08-26 2005-08-26 Sustained release pharmaceutical preparation containing carvedilol

Publications (1)

Publication Number Publication Date
ATE418969T1 true ATE418969T1 (de) 2009-01-15

Family

ID=89986232

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06779688T ATE418969T1 (de) 2005-08-26 2006-08-23 Carvedilol enthaltende pharmazeutische zusammensetzung mit kontrollierter freisetzung

Country Status (11)

Country Link
EP (1) EP1928431B8 (de)
AT (1) ATE418969T1 (de)
DE (1) DE602006004610D1 (de)
DK (1) DK1928431T3 (de)
EA (1) EA013058B1 (de)
ES (1) ES2321980T3 (de)
HU (1) HU227490B1 (de)
NO (1) NO20081481L (de)
PL (1) PL1928431T3 (de)
PT (1) PT1928431E (de)
WO (1) WO2007023325A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
KR20140088230A (ko) * 2006-01-27 2014-07-09 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
EP2037927B1 (de) 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
JP5793828B2 (ja) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
KR20090045945A (ko) 2006-08-25 2009-05-08 베링거 인겔하임 인터내셔날 게엠베하 제어 방출 시스템 및 이의 제조방법
HU227881B1 (en) * 2007-02-23 2012-05-29 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Sustained release pharmaceutical preparation containing carvedilol
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
PL2187876T3 (pl) 2007-09-21 2013-01-31 Evonik Roehm Gmbh Farmaceutyczna kompozycja opioidowa o zależnym od pH kontrolowanym uwalnianiu z odpornością przed wpływem etanolu
WO2009047800A2 (en) * 2007-10-09 2009-04-16 Lupin Limited Oral controlled release composition of carvedilol
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
CN103099793B (zh) * 2013-02-06 2015-07-15 中国人民解放军第二军医大学 片剂及其制备方法
JP7336187B2 (ja) * 2017-11-30 2023-08-31 日本ケミファ株式会社 多層構造を有する粒子状医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002065834A2 (en) * 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol
DE10209982A1 (de) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
WO2004056336A2 (en) * 2002-12-20 2004-07-08 Ranbaxy Laboratories Limited Controlled release, multiple unit drug delivery systems

Also Published As

Publication number Publication date
DK1928431T3 (da) 2009-04-20
EA200800666A1 (ru) 2008-06-30
ES2321980T3 (es) 2009-06-15
PT1928431E (pt) 2009-03-25
PL1928431T3 (pl) 2009-07-31
HU0500803D0 (en) 2005-11-28
EP1928431B8 (de) 2009-04-08
HUP0500803A3 (en) 2008-03-28
EP1928431B1 (de) 2008-12-31
NO20081481L (no) 2008-05-19
DE602006004610D1 (de) 2009-02-12
HU227490B1 (en) 2011-07-28
WO2007023325A2 (en) 2007-03-01
EA013058B1 (ru) 2010-02-26
WO2007023325A3 (en) 2007-06-28
HUP0500803A2 (en) 2007-05-29
EP1928431A2 (de) 2008-06-11

Similar Documents

Publication Publication Date Title
NO20081481L (no) Farmasoytisk sammensetning inneholdende carvedilol, med regulert frigivning
WO2009059701A3 (de) Retardtabletten mit hydromorphon
IL181117A0 (en) Sustained drug release composition demonstrating an ascending zero order release pattern, methods of manufacturing such a composition
WO2009036253A3 (en) Medical devices having bioerodable layers for the release of therapeutic agents
WO2009113703A3 (en) Orally-disintegrating solid preparation
TR201902233T4 (tr) Hızlı çözünen katı dozaj formu.
DE502005009109D1 (de) Feste, oral applizierbare pharmazeutische darreichungsformen enthaltend rivaroxaban mit modifizierter freisetzung
WO2009009628A3 (en) Endoprosthesis coating
WO2011060256A3 (en) Bilayer tablet formulations
WO2010053337A3 (ko) 서방성 미립자 및 이의 제조방법
WO2010053306A3 (ko) 메칠페니데이트의 방출 제어용 약제학적 조성물
WO2009058950A3 (en) Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
CL2009000550A1 (es) Metodo para mantener el estado de latencia de una semilla y evitar la germinacion de la misma que comprende revestir dicha semilla con una composicion que comprende particulas que contienen un material de nucleo, el cual comprende un material de cambio de fase.
FI20085543L (fi) Irrokemateriaalikoostumus, pohjamateriaali ja menetelmä pohjamateriaalin valmistamiseksi, pintakäsittelyaine pohjamateriaalia varten sekä pintakäsittelyaineen käyttö
CL2012002909A1 (es) Procedimiento de preparación de una composición farmacéutica que comprenden a) un centro granulado constituido por granos de principio activo aglomerados en presencia de aglomerante y b) una capa de recubrimiento de dicho centro granulado constituido por matriz grasa; composición farmacéutica; y su uso para administración oral
MX339587B (es) Pelicula que se puede rotular con laser resistente al calor.
WO2011101866A3 (en) Gastric retention formulation containing baclofen
ATE446743T1 (de) Mukosaler bioadhäsiver träger mit langsamer freisetzung zur abgabe von wirkstoffen
WO2006099514A3 (en) Drug delivery compositions and related methods
WO2010022132A3 (en) Biocompatible coatings, and methods of making and using the same
WO2007041367A3 (en) Oral composition containing a salivation inducing agent
CL2007000734A1 (es) Revestimiento de oxido inorganico transparente producido al preparar composicion de revestimiento que comprende particulas de oxido inorganico y polimero, aplicar composicion sobre sustrato, formar revestimiento y calentar el revestimiento para elimi
WO2012091408A3 (en) Matrix type antimicrobial vehicle and manufacturing method thereof
WO2010014952A3 (en) Extended release tablet and method for making and using same
MX280211B (es) Polimero, un metodo para producir el polimero y una mezcla de cemento que utiliza el mismo.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1928431

Country of ref document: EP